Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 ConferenceProactive Investors • 11/01/24
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study DataGlobeNewsWire • 11/01/24
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer's therapyProactive Investors • 10/31/24
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 MillionGlobeNewsWire • 10/31/24
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesityProactive Investors • 10/30/24
Tiziana Life Sciences awarded $4M to advance Alzheimer's disease researchProactive Investors • 09/19/24
Tiziana Life Sciences secures FDA Fast Track status for MS therapy intranasal foralumabProactive Investors • 07/24/24
Tiziana Life Sciences secures FDA approval to dose first patient with moderate Alzheimer's with investigational therapyProactive Investors • 06/26/24
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with ForalumabGlobeNewsWire • 06/26/24
Tiziana Life Sciences seeks FDA Fast Track Designation for foralumab in MS treatmentProactive Investors • 06/11/24
Tiziana Life Sciences reports qualitative improvement in MS patients treated with lead assetProactive Investors • 06/06/24
Tiziana Life Sciences seeks funding from ALS Association for intranasal foralumab trialProactive Investors • 06/04/24
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis ResearchGlobeNewsWire • 05/30/24
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal ForalumabGlobeNewsWire • 05/13/24
Tiziana Life Sciences unveils positive neuroimaging data for foralumab in MS patientsProactive Investors • 04/25/24
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal ForalumabGlobeNewsWire • 04/25/24
Tiziana Life Sciences wins FDA approval to add patients to Multiple Sclerosis Expanded Access ProgramProactive Investors • 04/23/24
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access ProgramGlobeNewsWire • 04/23/24